Funder
Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77.
2. Blay JY, Le Cesne A, Mermet C, Maugard C, Ravaud A, Chevreau C, et al. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood. 1998;92(2):405–10.
3. Wang Z, Cai XJ, Chen LY, Cheng B, Shi L, Lei L, et al. Factors potentially associated with gemcitabine-based chemotherapy-induced thrombocytopenia in Chinese patients with nonsmall cell lung cancer. J Cancer Res Ther. 2018;14(Suppl):S656–60.
4. Takahashi N, Sunaga T, Fujimiya T, Kurihara T, Nagatani A, Yamagishi M, et al. Risk associated with severe hematological toxicity in patients with urothelial cancer receiving combination chemotherapy of gemcitabine and cisplatin. Chemotherapy. 2020;65(1–2):29–34.
5. Takahashi M, Takahashi K, Kaneda H, Kawaguchi T, Nagayama K. Pretreatment platelet count and neutrophil/lymphocyte ratio are predictive markers for carboplatin plus pemetrexed therapy-induced thrombocytopenia. Anticancer Res. 2021;41(11):5729–37.